Literature DB >> 12393276

Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia.

Martin L Lesser1, Gordon W Dewald, Cristina P Sison, Richard T Silver.   

Abstract

Change in proportion of metaphases with a Ph chromosome is often used to measure effect of treatment in chronic myelocytic leukemia, but this method requires analysis of dividing cells. Dual-color fluorescence in situ hybridization (D-FISH) analysis of bone marrow (BM) or blood (PB), can be used to establish the proportion of interphase nuclei with BCR/ABL fusion. We studied the correlation of these three measures with each other and with response classification categories. In a clinical trial to test rIFN(-) versus rIFN(-) +Ara-C (N = 65 patients), we defined for each cytogenetic and FISH parameter, the patient's "best response" over time and at any given time. The strength and nature of agreement among the three measurements were determined by regression, correlation, and kappa statistic. Correlations between cyBM versus D-FISH-BM, cyBM versus D-FISH-PB and D-FISH-BM vs. D-FISH-PB were fairly strong. Regression showed cyBM values were significantly higher than those of D-FISH-PB or D-FISH-BM. No difference between D-FISH-PB and D-FISH-BM was apparent. When numerical responses (BR%) were classified into response categories (CR, PR, MR, NR), levels of agreement were weak to moderate. We observed a trend toward disagreement between cyBM and each D-FISH method, with cyBM tending to "downgrade" response category. Whether analyzed using actual numerical values or classified into response categories, cyBM differed from D-FISH-BM or D-FISH-PB. The results indicate that mixing data of different methods to measure treatment response within or between patients may be misleading clinical index.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393276     DOI: 10.1016/s0165-4608(02)00558-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.

Authors:  Naoto Takahashi; Ikuo Miura; Yoshimi Kobayashi; Masaaki Kume; Tomoko Yoshioka; Wataru Otane; Kaori Ohtsubo; Kaoru Takahashi; Atsushi Kitabayashi; Yoshinari Kawabata; Makoto Hirokawa; Hirokazu Nishijima; Ryo Ichinohasama; John Decoteau; Akira B Miura; Ken-Ichi Sawada
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 2.  Interpretation of cytogenetic and molecular results in patients treated for CML.

Authors:  Carlos E Vigil; Elizabeth A Griffiths; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2011-03-17       Impact factor: 8.250

Review 3.  Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.

Authors:  Elias Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.